MediciNova, Inc. announced that Good Manufacturing Practice -based Master Virus Seed Stock production of its novel intranasal SARS-CoV-2 vaccine for COVID-19, using BC-PIV technology, has been initiated at Millipore Sigma BioReliance Services, a group company of Merck KGaA, Darmstadt, Germany.
November 24, 2020
· 6 min read